Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00353574 · ClinicalTrials.gov registry record · Phase 3
DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension
A Phase 3 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 282
- Enrollment target
NCT00353574: Clinical Trial Phase 3 study, sponsored by Gilead Sciences.
NCT00353574 is a Phase 3 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 282 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00353574, a Phase 3 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 282 participants
- Enrollment target
Study Summary
This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the U.S., which means that a doctor cannot prescribe this drug. The purpose of this study is to evaluate the long-term safety of darusentan in subjects with resistant systolic hypertension despite treatment with full doses of three or more antihypertensive medications, including a diuretic.
Interventions
- DRUG Darusentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2006-09 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
Why NCT00353574 stopped before completion
NCT00353574 is an interventional study that assigns participants to a tested intervention. The registered 282 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 1 intervention - of which Darusentan is the first listed.
NCT00353574 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00353574 about?
NCT00353574 is a clinical study titled "DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension". This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the U.S., which means that a doctor cannot prescribe this drug. The purpose of this study is to evaluate the long-term...
What is the current status of trial NCT00353574?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 282 participants. The study started on 2006-09. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00353574?
The interventions under investigation include: Darusentan (DRUG).
Who is sponsoring clinical trial NCT00353574?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00353574's enrollment target sits among peer trials
282 1194th of 2000 higher than 807 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
- NCT05101070 · 282 participants · Phase 1
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
- NCT06276491 · 282 participants · Phase 1
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia